[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Margan Biotech\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100638924",false,"NCT07580846","ATENEA Study: Adherence to Creatine-Based Nutritional Supplementation in Estrogen-Depleted Women","AssessmenT of thE Adherence of Nutritional Supplementation With Creatine Formula in Estrogen-Depleted Adult Women: Prospective Clinical Investigation","ATENEA","Inclusion Criteria:\n\n* Biological female sex.\n* Age ≥40 years.\n* Estrogen-depleted status, defined as at least one of the following:\n\nnatural menopause, defined as amenorrhea for ≥12 consecutive months; surgically induced menopause; late perimenopause with elevated FSH according to clinical judgment.\n\n* Absence of major comorbidities that would contraindicate use of the nutritional supplement or the recommended physical activity.\n* No relevant changes in usual treatment during the previous 3 months.\n* Ability to understand the study information and provide written informed consent.\n* Willingness to take the nutritional supplement according to the study instructions.\n* Willingness to follow general physical activity recommendations provided by the investigator.\n* Willingness and ability to attend the planned visits and complete study assessments through Week 12.\n\nExclusion Criteria:\n\n* Initiation or modification of treatment with GLP-1 receptor agonists within the previous 12 weeks.\n* Presence of musculoskeletal or joint conditions that significantly limit the ability to perform regular physical activity or study-related functional assessments.\n* Clinically relevant renal or hepatic disease.\n* Current use of diuretics or potentially nephrotoxic medications.\n* Known allergy or intolerance to any component of the nutritional supplement.\n* Participation in another clinical study (nutritional, pharmacological, or interventional) within the previous 3 months.\n* Any medical condition or social circumstance that, in the investigator's judgment, could interfere with study participation, adherence, or data validity.",true,"FEMALE","40 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, observational clinical study conducted under routine clinical practice conditions aimed at describing adherence to a creatine-based nutritional supplement (Creaticare FEM) in estrogen-depleted adult women. Participants will receive the supplement for 12 weeks, and adherence will be assessed as the percentage of doses consumed and the proportion of participants achieving ≥80% adherence. Secondary outcomes include persistence, satisfaction, tolerability, and adherence to recommended physical activity. Exploratory outcomes include changes in muscle strength, body composition, quality of life, joint pain, and skin health.",[26,27],"Menopause","Estrogen Deficiency",[29,26,30,31,32,33],"Creatine","Women´s Health","Estrogen deficiency","Collagen","Dietary supplements","RECRUITING","2026-05-05",{"date":37,"type":38},"2026-05-12","ACTUAL",{"date":40,"type":38},"2026-03-20",{"date":42,"type":22},"2026-10-01",{"name":44,"class":45},"Margan Biotech","INDUSTRY",4,""]